[HTML] nature.com

[HTML][HTML] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British journal of …, 2014 - nature.com
Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …
被引用次数：465 相关文章

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JY Douillard, G Ostoros, M Cobo… - British journal of …, 2014 - pubmed.ncbi.nlm.nih.gov
Background Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …

[引用][C] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JY DOUILLARD, G OSTOROS, M COBO… - British journal of …, 2014 - pascal-francis.inist.fr
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label,
single-arm study CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic …

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British Journal of …, 2013 - europepmc.org
Background Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …

[引用][C] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British Journal of …, 2013 - cir.nii.ac.jp
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label,
single-arm study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ …

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

JY Douillard, G Ostoros, M Cobo… - British Journal of …, 2014 - search.ebscohost.com
Abstract Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess
efficacy and safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV …
[HTML] nih.gov

[HTML][HTML] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British Journal of …, 2014 - ncbi.nlm.nih.gov
Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …
[HTML] nih.gov

[HTML][HTML] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British Journal of …, 2014 - ncbi.nlm.nih.gov
Background: Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

JY Douillard, G Ostoros, M Cobo, T Ciuleanu… - British Journal of …, 2013 - europepmc.org
Background Phase-IV, open-label, single-arm study (NCT01203917) to assess efficacy and
safety/tolerability of first-line gefitinib in Caucasian patients with stage IIIA/B/IV, epidermal …

[引用][C] First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study

J Douillard, G Ostoros, M Cobo… - The British Journal …, 2014 - Nature Publishing Group